

# Prevention of Restenosis in CLI Patients

**Roberto Ferraresi**

Peripheral Interventional Unit

[www.robtoferraresi.it](http://www.robtoferraresi.it)



# Prevention of Restenosis

in CLI Patients

Clinical Experience Milan 2010-2013

CLI disease patterns

Revascularization targets and lesion mean length

BTK-CLI treatment (devices)

Studies and Clinical Cases Evidence

Healing time in RTF 5-6 Patients

Restenosis Rate and Significance in CLI patients

- Case 1


Restenosis in BTK vessels

Conclusions

**1)**

**Pattern of disease in CLI patients**


# Pattern of disease in CLI patients



## CLI “real world” patients 2010-2013, our diabetic foot clinic

- 1,343 patients → 1,589 legs (first angiographic study)
- All CLI patients (Rutherford 4-5-6)
- Mean age 72 yrs
- 82% DM
- 46% smokers/ex-smokers
- 20% end-stage-renal-disease in hemodialysis
- 75% high blood pressure

# Pattern of disease in CLI patients



5% above-the-groin (ATG)

53% FEM-POP

95% BTK

TPT	<b>32%</b>	
0 BTK vessel	<b>5%</b>	
1 BTK vessel	<b>15%</b>	
2 BTK vessels	<b>43%</b>	<b>80%</b>
3 BTK vessels	<b>37%</b>	

# Pattern of disease in CLI patients



5% above-the-groin (ATG)



53% FEM-POP




95% BTK




TPT	32%	
0 BTK vessel	5%	
1 BTK vessel	15%	
2 BTK vessels	43%	80%
3 BTK vessels	37%	

# Pattern of disease in CLI patients



0 FOOT vessel	<b>26%</b>	
1 FOOT vessel	<b>22%</b>	
2 FOOT vessels	<b>31%</b>	<b>52%</b>
3 FOOT vessels	<b>21%</b>	
ARCH	<b>26%</b>	


# Pattern of disease in CLI patients



0 FOOT vessel	26%	
1 FOOT vessel	22%	
2 FOOT vessels	31%	52%
3 FOOT vessels	21%	
ARCH	26%	




## Pattern of disease in CLI patients




### Conclusions

1. Above-the-groin disease is not common in a diabetic-foot clinic, because this localization is not related to diabetes
2. Fem-pop disease is present in more than half of the patients
3. BTK & FOOT vessel disease is an emergent cause of CLI: 80% of the patients have 2 or 3 BTK vessels disease, 52% of the patients have 2 or 3 FOOT vessels disease



1)

**...epidemic of OLD-DM-ESRD-  
CLI pts: multilevel disease &  
extensive involvement of  
BTK&FOOT vessels**



1)

...epidemic of OLD-DM-ESRD-CLI pts: multilevel disease & extensive involvement of BTK&FOOT vessels

2)

**Targets in CLI revascularization**

# Targets in CLI revascularization

## 1. Complete revascularization

- 1 vessel better than 0
- 2-3 vessels better than 1
- Tibials better than peroneal

DIABETICMedicine  
DOI: 10.1111/j.1464-5491.2007.02167.x

**When is a technically successful peripheral angioplasty effective in preventing above-the-ankle amputation in diabetic patients with critical limb ischaemia?**

Cardiovasc Intervent Radiol (2010) 33:720–725  
DOI 10.1007/s00270-010-9881-3


CLINICAL INVESTIGATION

**PTA of Infrapopliteal Arteries: Long-term Clinical Follow-up and Analysis of Factors Influencing Clinical Outcome**

Jan H. Peregrin · Boris Kožnar · Josef Kováč ·  
Jarmila Laštovíková · Jiří Novotný ·  
Daniel Vedlich · Jelena Skibová

Healing is a blood-flow dependent phenomenon and the first principle guiding our revascularization strategy must be giving to the foot the best possible blood supply.

## Complete revascularization



Complete revascularization



# Targets in CLI revascularization

1. Complete revascularization

2. WRA Revascularization



Complete revascularization could not be possible to achieve in many cases due to different reasons:

- Technical failure
- Time failure (patient stress, contrast dye amount, etc.)

Revascularization of a Specific Angiosome for Limb Salvage: Does the Target Artery Matter?

Richard F. Neville,<sup>1</sup> Christoph Michael Thomassen,<sup>2</sup> and An


Importance of the Angiosome Concept in Endovascular Therapy in Patients with Critical Limb Ischemia

Osamu Iida,<sup>1</sup> MD, Shinsuke Nanto,<sup>2†</sup> MD, PhD, Masaaki Uematsu, Kuniyasu Ikeoka,<sup>1</sup> MD, Shin Okamoto,<sup>3</sup> MD, Tomoharu Dohi,<sup>1</sup> MD, Masashi Fujita,<sup>1</sup> MD, PhD, Hiroto Terashi,<sup>3</sup> MD, PhD, and Seiji Nagata,<sup>1</sup> MD, PhD

A reliable approach to diabetic neuroischemic foot wounds: below-the-knee angiosome-oriented angioplasty.

Alexandrescu V, Vincent G, Azdad K, Hubermont G, Ledent G, Ngongang G, Filimon AM

WRA rev. in a "desert foot"



## PATIENT DATA

- 69-year-old male
- Type 2 DM
- ESRD in hemodialysis
- Forefoot plantar ulcer



## Targets in CLI revascularization

### 1. Complete revascularization

- 1 vessel better than 0
- 2-3 vessels better than 1
- Tibials better than peroneal

### 2. WRA Revascularization

- Direct revascularization (bypass or PTA) better than indirect revascularization

**How much vessel have we to treat to achieve these goals?**

# Mean length of the single treated lesion



5% ATG

60±53 mm


53% FEM-POP

121±113 mm



95% BTK

188±121 mm

Mean length of the treated vessel in a single limb/procedure



28.5 cm





1)

...epidemic of OLD-DM-ESRD-CLI pts: multilevel disease & extensive involvement of BTK&FOOT vessels

2)

**Complete/WRA PTA → we have to treat a lot of vessel to gain healing!**



1)

...epidemic of OLD-DM-ESRD-CLI pts: multilevel disease & extensive involvement of BTK&FOOT vessels


2)

Complete/WRA PTA → we have to treat a lot of vessel to gain healing!

3)

**BTK-CLI angioplasty**

# Mean length of the treated lesion




18 studies with Balloon expandable stents in BTK arteries:

- Bare Metal Stents (BMS)
- Absorbable Metal Stent (AMS)
- Drug-Eluting Stents (DES)
  - Sirolimus-Eluting Stent (SES)
  - Everolimus-Eluting Stent (EES)
  - Paclitaxel-Eluting Stent (PES)

Published studies on BTK angioplasty

# Mean length of the treated lesion




**36 mm (11-97)**

In this slide we don't want to show the results regarding patency (DES better than BMS better than POBA etc.).

**The aim of the slide is to show the mean length of the treated lesions collected in these studies!**

**Published studies on BTK angioplasty**

# Mean length of the treated lesion




Observe the difference between the mean length of the treated lesion in these studies and our real world of CLI-BTK lesions!

Published studies on BTK angioplasty




# Mean length of the treated lesion




Published studies on BTK angioplasty

# Mean length of the treated lesion




Published studies on BTK angioplasty

# Mean length of the treated lesion




Published studies on BTK angioplasty




# Mean length of the treated lesion



**Only POBA (UB & DEB) can treat the long lesions typical of BTK&FOOT vessel disease in CLI patients**



**Published studies on BTK angioplasty**



1)

...epidemic of OLD-DM-ESRD-CLI pts: multilevel disease & extensive involvement of BTK&FOOT vessels

2)

Complete/WRA PTA → we have to treat a lot of vessel to gain healing!


3)

Only POBA (UB&DEB) can treat the long lesions typical of BTK&FOOT vessel disease

4)

Wound-healing time in Rtf 5-6 pts

## Healing time in Rutherford 5-6



1. Xcell Trial – Rocha Sing 2011
2. Soderstrom, et al. Journal of Vascular Surgery 2009
3. Soderstrom, et al. Eur J Vasc Endovasc Surg 2008
4. Hoffman, et al. Eur J Vasc Endovasc Surg 2007
5. Chung, et al. Journal of Vascular Surgery 2006

**Courtesy Rocha Sing 2011**






**$\geq 6$  months**

**The picture shows six Rutherford 6 feet when they arrived at our clinic and 6 months later**







1)

...epidemic of OLD-DM-ESRD-CLI pts: multilevel disease & extensive involvement of BTK&FOOT vessels

2)

Complete/WRA PTA → we have to treat a lot of vessel to gain healing!

3)




Only POBA (UB&DEB) can treat the long lesions typical of BTK&FOOT vessel disease

4)

Wound healing time in Rtf 5-6 pts is  $\geq 6$  m, and complete 6m healing rate <50%

$\geq 6$  months!





1)

...epidemic of OLD-DM-ESRD-CLI pts: multilevel disease & extensive involvement of BTK&FOOT vessels

2)

Complete/WRA PTA → we have to treat a lot of vessel to gain healing!

3)

Only POBA (UB&DEB) can treat the long lesions typical of BTK&FOOT vessel disease

4)

Wound healing time in Rtf 5-6 pts is ≥6 m, and complete 6m healing rate <50%




5)

Restenosis rate and significance in CLI patients


# Restenosis rate in real-world, long BTK vessels

## Uncoated balloons

Study	limbs	Mean lesion length	Follow up	restenosis	TLR
<p>Catheterization and Cardiovascular Interventions 76:1047-1054 (2010)</p> <p><b>Angiographic Patency and Clinical Outcome After Balloon-Angioplasty for Extensive Infrapopliteal Arterial Disease</b></p> <p>Andrej Schmidt,<sup>1,2*</sup> MD, Matthias Ulrich,<sup>1</sup> MD, Bert Winkler,<sup>1</sup> Christina Klaeffling,<sup>3</sup> MD, Yvonne Bausback,<sup>1</sup> MD, Sven Bräunlich,<sup>1</sup> MD, Spiridon Botsios,<sup>4</sup> MD, Hans-Joachim Kruse,<sup>5</sup> MD, Ramon L. Varcoe,<sup>6</sup> FRACS (VASC), MD, Steven Kum,<sup>1</sup> MD, and Dierk Scheinert,<sup>1,2</sup> MD</p>	62	18.4 cm	3 m	69%	50%
<p>European Journal of Vascular and Endovascular Surgery 44 (2012) 425-431</p> <p>Contents lists available at ScienceDirect</p> <p>European Journal of Vascular and Endovascular Surgery  Journal</p> <p>journal homepage: www.ejves.com</p> <p><b>Angiographic Restenosis and Its Clinical Impact after Infrapopliteal Angioplasty</b></p> <p>O. Iida<sup>a,*</sup>, Y. Soga<sup>b</sup>, D. Kawasaki<sup>c</sup>, K. Hirano<sup>d</sup>, T. Yamaoka<sup>e</sup>, K. Suzuki<sup>f</sup>, Y. Miyashita<sup>g</sup>, H. Yokoi<sup>b</sup>, M. Takahara<sup>h</sup>, M. Uematsu<sup>g</sup></p>	68	14.0 cm	3 m	73%	40%
			12 m	82%	48%


Restenosis rate in real-world, long BTK vessels  
Uncoated balloons

**3 months!**



Restenosis in extensive BTK-  
FOOT-PTA is precocious and  
aggressive: 70% at 3 months

# Delay of healing in patients with restenosis



**Figure 5.** Comparison of frequency of complete ulcer healing or lack of rest pain with and without restenosis after 3 and 12 months.

# Delay of healing in patients with restenosis

Restenosis delays healing of tissue lesions!




European Journal of Vascular and Endovascular Surgery

Contents lists available at SciVerse ScienceDirect

journal homepage: www.ejves.com

Angiographic Restenosis and Its Clinical Impact after Infrapopliteal

O. Iida<sup>a,\*</sup>, Y. Soga<sup>b</sup>, D. Kawasaki<sup>c</sup>, K. Hirano<sup>d</sup>, T. Yamaoka<sup>e</sup>, K. Suzuki<sup>f</sup>, Y. Miyashita<sup>g</sup>, H. Yokoi<sup>h</sup>, M. Takahara<sup>h</sup>, M. Uematsu<sup>g</sup>



**Figure 5.** Comparison of frequency of complete ulcer healing or lack of rest pain with and without restenosis after 3 and 12 months.

## PATIENT DATA

- 84-year-old male
- Type 2 DM/HBP/ex-smoker
- Ischemic cerebrovascular disease
- Left foot: 1° toe gangrene → 1° toe amputation → dehiscence of the surgical wound



***Sent to our diabetic foot clinic  
on August 2011***







1° PTA: 3/08/2011 → basal













2° PTA: + 6 months → 6 m






**3° PTA: + 5 months → 11 m**






4° PTA: + 4 months → 15 m



5° PTA: + 5 months → 20 m



6° PTA: + 6 months → 26 m



**1° PTA  
3/08/2011**








**2° PTA  
+ 5 months**

**3° PTA  
+ 5 months**

**4° PTA  
+ 4 months**

**5° PTA  
+ 5 months**

**6° PTA  
+ 6 months**



**Different operators → different results**

**1° PTA  
3/08/2011**






**2° PTA  
+ 5 months**

**3° PTA  
+ 5 months**

**4° PTA  
+ 4 months**

**5° PTA  
+ 5 months**

**6° PTA  
+ 6 months**



**Restenosis after uncoated balloon angioplasty was always precocious and aggressive!**

1° PTA  
3/08/2011



2° PTA  
+ 5 months



3° PTA  
+ 5 months



4° PTA  
+ 4 months



5° PTA  
+ 5 months



6° PTA  
+ 6 months



26 months of recurrent pain, inability to walk, infections, medications, hospitalizations, multiple "minor" amputations...  
This is what we call "limb salvage"!





# Restenosis rate in BTK vessels

## Meta-analysis of infrapopliteal angioplasty for chronic critical limb ischemia

Marcello Romiti, MD,\* Maximiano Albers, MD,\* Francisco Cardoso Brochado-Neto, MD,\* Anai Espinelli S. Durazzo, MD,<sup>†</sup> Carlos Alberto Bragança Pereira, PhD,\* and Nelson De Luccia, MD,<sup>†</sup> Santos and São Paulo, São Paulo, Brazil

30 articles  
between  
1990-2006




Fig 2. Meta-analysis estimates of primary patency (black line), secondary patency (gray line), limb salvage (red line).

Limb salvage




Secondary patency

Primary patency


TLR




Primary angioplasty + TLR obtain a high limb salvage rate, but in the struggle against CLI we must pursue different and finer targets:

- Time to healing/Reulceration rate
- Time to walking/QoL evaluation




- 1) ...epidemic of OLD-DM-ESRD-CLI pts: multilevel disease & extensive involvement of BTK&FOOT vessels
- 2) Complete/WRA PTA → we have to treat a lot of vessel to gain healing!
- 3) Only POBA (UB&DEB) can treat the long lesions typical of BTK&FOOT vessel disease
- 4) Wound healing time in Rtf 5-6 pts is ≥6 m, and complete 6m healing rate <50%
- 5) Restenosis rate and significance in CLI patients





**We have got a problem!  
How can we fight  
restenosis in CLI  
patients?**

- 1) ...epidemic of OLD-DM-ESRD-CLI pts: multilevel disease & extensive involvement of BTK&FOOT vessels
- 2) Complete/WRA PTA → we have to treat a lot of vessel to gain healing!
- 3) Only POBA (UB&DEB) can treat the long lesions typical of BTK&FOOT vessel disease
- 4) Wound healing time in Rtf 5-6 pts is ≥6 m, and complete 6m healing rate <50%
- 5) Restenosis rate and significance in CLI patients




# Percutaneous coronary intervention evolution

Decreasing incidence of restenosis

Decreasing invasiveness of surgical procedure

*“Evolution fuel”*




# BTK-PTA: a coronary-like evolution?

↑  
Decreasing incidence of restenosis

↑  
Decreasing invasiveness of surgical procedure

*“Evolution fuel”*




# BTK-PTA: a coronary-like evolution?

Decreasing incidence of restenosis

Decreasing invasiveness of surgical procedure

*“Evolution fuel”*




# BTK-PTA: a coronary-like evolution?

Decreasing incidence of restenosis

Decreasing invasiveness of surgical procedure


*“Evolution fuel”*



# Conclusions


1)

In short BTK lesions (<5cm) there is increasing evidence about good acute and mid-term results of primary stenting. BMSs, DESs and SESs seem to be promising devices in prevention of restenosis





# Conclusions




1)

In short BTK lesions (<5cm) there is increasing evidence about good acute and mid-term results of primary stenting. BMSs, DESs and SESs seem to be promising devices in prevention of restenosis

2)

In long diffuse lesions (majority of CLI patients) the optimal endovascular treatment is POBA with dedicated BTK balloons + bailout stenting

# Conclusions



1)

In short BTK lesions (<5cm) there is increasing evidence about good acute and mid-term results of primary stenting. BMSs, DESs and SESs seem to be promising devices in prevention of restenosis

2)

In long diffuse lesions (majority of CLI patients) the optimal endovascular treatment is POBA with dedicated BTK balloons + bailout stenting

3)

The future is open for every device able to demonstrate safety and efficacy in treating long BTK & FOOT vessel disease, improving patency, reducing TLR, healing time and reulceration rate

